Loading company…
SEngine Precision Medicine is a biotechnology company offering personalized cancer treatment testing through its PARIS Test.
SEngine Precision Medicine, founded in 2015 and based in Seattle, US, runs the PARIS Test, a lab test that screens a patient's tumor sample against a custom panel of up to 42 oncology drugs. Oncologists use the results to identify potentially effective therapies, and the test is billed per case to healthcare providers. In July 2022 the company raised USD 10.00 mn in Series A funding led by WRF Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in